Overview

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

Status:
Not yet recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

Phase:

Phase 3

Details

Lead Sponsor:

Scynexis, Inc.

Treatments:

Anidulafungin
Caspofungin
Echinocandins
Fluconazole
Ibrexafungerp
Micafungin